作者: Naomi Kobayashi , Yutaka Inaba , Makoto Uchiyama , Hiroyuki Ike , So Kubota
DOI: 10.1016/J.ARTH.2015.07.017
关键词: Bone Density Conservation Agents 、 Teriparatide 、 Medicine 、 Surgery 、 Dual-energy X-ray absorptiometry 、 Randomized controlled trial 、 Periprosthetic 、 Osteoporosis 、 Bone mineral 、 Bone density
摘要: In this study, the effect of teriparatide for prevention bone mineral density (BMD) loss after THA was compared with alendronate in a randomized controlled trial. Forty-eight patients were assigned to three groups, namely, teriparatide, alendronate, and no medication groups. Dual-energy x-ray absorptiometry (DEXA) performed at 1 week post-surgery as baseline reference, followed by subsequent measurements 12, 24, 48 weeks postoperatively. For periprosthetic BMD loss, significant demonstrated, though its similar alendronate. On other hand, higher lumbar observed group than post-surgery. Teriparatide administration may be one reasonable option osteoporotic patient preserve THA.